SCAI 专家共识声明 关于治疗静脉静脉复原和静脉血栓的管理
Lloyd W Klein1, Sandeep Nathan2, Akiko Maehara3
1Division of Cardiology, University of California, San Francisco, San Francisco, California.
概括
支架失败,包括支架内缩和支架血栓形成,是冠状动脉支架的主要问题. 这份共识声明提供了评估和管理的更新算法,强调冠心内成像以获得最佳治疗.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 支架失败,包括支架内缩和支架血栓形成,仍然是冠状动脉支架的重大限制.
- 尽管在支架设计和涂层方面取得了进展,但支架静止症仍然是一个常见的临床问题,带来了大量的医疗费用和不良后果.
- 支架血栓导致动脉突然关闭,增加心肌梗塞和死亡的风险.
研究的目的:
- 提供最新的实用算法方法来管理静脉静脉复缩和静脉血栓形成.
- 为评估和管理经历支架失败的患者提供一个务实的概要.
- 提出一种新的时间敏感的分类,用于机械含义的实体缩.
主要方法:
- 基于时间和机制,开发一种新的静脉静脉复缩的分类系统.
- 强调频繁使用冠状动脉内成像,以精确地确定病因.
- 对患者评估和治疗支架失败的算法方法.
主要成果:
- 提出了一个新的时间敏感分类,用于静脉静脉复缩.
- 冠内成像被强调为指导治疗选择的关键.
- 建议在初始植入时使用图像引导的支架,以尽量减少未来的支架失败.
结论:
- 通过成像和时间来准确诊断支架失败的病因,对于有效的治疗至关重要.
- 心血管血管血管学与干预协会 (SCAI) 建议对支架失效进行更新的管理策略.
- 建议在初始支架和随后的失败事件期间主动使用冠状动脉内成像.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Aneurysm III: Interprofessional Care
478
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
478


